Who makes UCT-03-008?

UCT-03-008 is developed by 1200 Pharma, LLC.

Last reviewed 2026-04-19 · How we verify

UCT-03-008

1200 Pharma, LLC · Phase 1 active Small molecule

At a glance

Generic name	UCT-03-008
Sponsor	1200 Pharma, LLC
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

UCT-03-008 CI brief — competitive landscape report
UCT-03-008 updates RSS · CI watch RSS
1200 Pharma, LLC portfolio CI